- Home
- MGNX vs KRRO Comparison
MGNX vs KRRO Comparison
Compare MGNX & KRRO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MGNX
- KRRO
- Stock Information
- Founded
- MGNX 2000
- KRRO 2014
- Country
- MGNX United States
- KRRO United States
- Employees
- MGNX N/A
- KRRO N/A
- Industry
- MGNX Biotechnology: Pharmaceutical Preparations
- KRRO Biotechnology: Pharmaceutical Preparations
- Sector
- MGNX Health Care
- KRRO Health Care
- Exchange
- MGNX Nasdaq
- KRRO Nasdaq
- Market Cap
- MGNX 87.7M
- KRRO 101.4M
- IPO Year
- MGNX 2013
- KRRO 2019
- Fundamental
- Price
- MGNX $1.33
- KRRO $12.35
- Analyst Decision
- MGNX Hold
- KRRO Strong Buy
- Analyst Count
- MGNX 9
- KRRO 7
- Target Price
- MGNX $5.33
- KRRO $85.67
- AVG Volume (30 Days)
- MGNX 2.0M
- KRRO 200.2K
- Earning Date
- MGNX 08-05-2025
- KRRO 08-12-2025
- Dividend Yield
- MGNX N/A
- KRRO N/A
- EPS Growth
- MGNX N/A
- KRRO N/A
- EPS
- MGNX N/A
- KRRO N/A
- Revenue
- MGNX $154,050,000.00
- KRRO $4,821,000.00
- Revenue This Year
- MGNX N/A
- KRRO $65.08
- Revenue Next Year
- MGNX N/A
- KRRO N/A
- P/E Ratio
- MGNX N/A
- KRRO N/A
- Revenue Growth
- MGNX 255.31
- KRRO N/A
- 52 Week Low
- MGNX $0.99
- KRRO $10.29
- 52 Week High
- MGNX $5.77
- KRRO $98.00
- Technical
- Relative Strength Index (RSI)
- MGNX 41.45
- KRRO 41.55
- Support Level
- MGNX $1.33
- KRRO $11.50
- Resistance Level
- MGNX $2.17
- KRRO $16.86
- Average True Range (ATR)
- MGNX 0.17
- KRRO 1.50
- MACD
- MGNX -0.02
- KRRO 0.01
- Stochastic Oscillator
- MGNX 2.38
- KRRO 31.35
About MGNX MacroGenics Inc.
Macrogenics Inc is a biotechnology company focused on discovering and developing antibody-based therapeutics for the treatment of cancer. Its product includes MARGENZA, which is for the treatment of adult patients with metastatic HER2-positive breast cancer. It's a pipeline of product candidates designed to target either various tumor-associated antigens or immune checkpoint molecules. The company has three proprietary product candidates in clinical development: lorigerlimab, a bispecific DART molecule that targets checkpoint inhibitors PD-1 and CTLA-4; MGC026, an ADC that targets B7-H3 and delivers a novel topoisomerase I inhibitor (TOP1i)-based linker-payload, and MGC028, an ADC that targets ADAM9 and delivers a novel TOP1i-based linker-payload.
About KRRO Korro Bio Inc.
Korro Bio Inc is a biopharmaceutical company with a mission to discover, develop, and commercialize a new class of genetic medicines based on editing RNA, enabling the treatment of both rare and highly prevalent diseases. It is generating a portfolio of differentiated programs that are designed to harness the body's natural RNA editing process to effect a precise yet transient single base edit. By editing RNA instead of DNA, Korro Bio is expanding the reach of genetic medicines by delivering additional precision and tunability.